New antibody drug enters human trials for Hard-to-Treat cancers
NCT ID NCT06276491
First seen Mar 17, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This early-stage trial is testing a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to standard treatments. The main goals are to see if the drug is safe and to find the best dose. About 282 participants will receive the drug, and researchers will monitor side effects and any tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Herlev Gentofte Hospital
NOT_YET_RECRUITINGHerlev, 2730, Denmark
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Montefiore Einstein Comprehensive Cancer Center
RECRUITINGThe Bronx, New York, 10461, United States
-
OU Health Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Stanford
RECRUITINGPalo Alto, California, 94304, United States
-
The John Theruer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
University of California
RECRUITINGSan Francisco, California, 94158, United States
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22903, United States
-
Winship Cancer Institute, Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XmAb541 (a bispecific antibody)
What this could lead to
If it works, this could point toward a new treatment option for certain advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial focused on safety, so it is unknown if XmAb541 will shrink tumors or improve survival. Side effects, including cytokine release syndrome, are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.